Topic 3: Innovative processing for sustainable, safe and nutritious food products
Bioceanics are interested in joining or co-developing a consortium involving contributes scientific and technological expertise to collaborative research on sustainable omega-3 production, innovative lipid ingredients and bioprocess development. Our activities connect laboratory research with process optimization, analytical characterization and pilot-scale validation.
- Bioequivalent of krill oil omega-3 without the environmental impact
- Enzymatic bioprocesses
- Technology transfer
- Industrial Scale-up
- Functional ingredients and nutraceutical
- Marine lipid biotechnology
Our expertise includes the development and optimization of sustainable biocatalytic processes, with particular emphasis on:
• Enzymatic biocatalysis: Selection and application of specialized enzymes for selective lipid modification.
• Enzyme immobilization: Development of immobilized biocatalysts to improve enzyme stability, operational performance, and reusability.
• Process optimization: Optimization of reaction conditions, conversion efficiency, and product yields.
• Bioprocess scale-up: Adaptation of laboratory-scale processes to pilot-scale production, considering process reproducibility and operational efficiency.
Bioceanics, S.L. is a deep-tech biotechnology company established as a spin-off of the Universidad Autonoma de Madrid, specializing in the creation and development of sustainable, high-value-added solutions derived from functional lipids for applications in the nutraceutical, pharmaceutical, and cosmetic industries.
Its project Vegan Biokrill introduces a structured microalgae-derived ingredient that replicates and functionally enhances traditional krill oil, eliminating the need for overexploited marine resources. Bioceanics core technology is based on a innovative enzymatic and complementary processing technologies to transform DHA and EPA-rich oils, particularly those derived from microalgae, into structured omega-3 phospholipids and lysophospholipids (LPC-DHA) characterized by high bioavailability and the potential for selective brain delivery via the Mfsd2a transporter.